NASDAQ:CPIX Cumberland Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cumberland Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.17 -0.07 (-2.16 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range$3.12Now: $3.17▼$3.2350-Day Range$3.16MA: $3.31▼$3.4852-Week Range$3.10Now: $3.17▼$6.10Volume14,493 shsAverage Volume28,689 shsMarket Capitalization$47.99 millionP/E RatioN/ADividend YieldN/ABeta0.39 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections. The company's Phase II product candidates includes Hepatoren injection for the treatment of critically ill patients suffering from liver and kidney failure; Boxaban oral capsules for the treatment of asthma patients; Vasculan oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as severe disabling psoriasis. The company markets and sells its products through sales representatives and district managers. Cumberland Pharmaceuticals Inc. has a strategic alliance with Clinigen Group plc and Nordic Group B.V. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCumberland Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.75, Cumberland Pharmaceuticals has a forecasted upside of 207.6% from its current price of $3.17.Amount of Analyst CoverageCumberland Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.2 Community Rank Outperform VotesCumberland Pharmaceuticals has received 184 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCumberland Pharmaceuticals has received 240 “underperform” votes. (Add your “underperform” vote.)Community SentimentCumberland Pharmaceuticals has received 56.60% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cumberland Pharmaceuticals and other stocks. Vote “Outperform” if you believe CPIX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CPIX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCumberland Pharmaceuticals does not currently pay a dividend.Dividend GrowthCumberland Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cumberland Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,781.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders39.72% of the stock of Cumberland Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.38% of the stock of Cumberland Pharmaceuticals is held by institutions. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Cumberland Pharmaceuticals are expected to grow by 2,300.00% in the coming year, from $0.01 to $0.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cumberland Pharmaceuticals is -9.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cumberland Pharmaceuticals is -9.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCumberland Pharmaceuticals has a P/B Ratio of 0.94. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 2.5 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.44 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:CPIX Previous Symbol CUSIP23077010 CIK1087294 Webwww.cumberlandpharma.com Phone615-255-0068Debt Debt-to-Equity Ratio0.35 Current Ratio2.02 Quick Ratio1.68Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio317.00 P/E GrowthN/A Sales & Book Value Annual Sales$47.53 million Price / Sales1.01 Cash Flow$0.50 per share Price / Cash Flow6.33 Book Value$3.36 per share Price / Book0.94Profitability EPS (Most Recent Fiscal Year)$0.23 Net Income$-3,540,000.00 Net Margins-11.65% Return on Equity3.38% Return on Assets1.69%Miscellaneous Employees80 Outstanding Shares15,139,000Market Cap$47.99 million Next Earnings Date11/10/2020 (Estimated) OptionableOptionable $3.17 -0.07 (-2.16 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CPIX News and Ratings via Email Sign-up to receive the latest news and ratings for CPIX and its competitors with MarketBeat's FREE daily newsletter. Cumberland Pharmaceuticals (NASDAQ:CPIX) Frequently Asked Questions How has Cumberland Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)? Cumberland Pharmaceuticals' stock was trading at $4.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CPIX stock has decreased by 23.4% and is now trading at $3.17. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Cumberland Pharmaceuticals? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cumberland Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cumberland Pharmaceuticals. When is Cumberland Pharmaceuticals' next earnings date? Cumberland Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Cumberland Pharmaceuticals. How were Cumberland Pharmaceuticals' earnings last quarter? Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) posted its quarterly earnings results on Wednesday, May, 20th. The specialty pharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.02 by $0.01. The specialty pharmaceutical company earned $8.33 million during the quarter, compared to analysts' expectations of $9.46 million. Cumberland Pharmaceuticals had a positive return on equity of 3.38% and a negative net margin of 11.65%. View Cumberland Pharmaceuticals' earnings history. What price target have analysts set for CPIX? 1 analysts have issued 1 year price targets for Cumberland Pharmaceuticals' shares. Their forecasts range from $9.75 to $9.75. On average, they anticipate Cumberland Pharmaceuticals' share price to reach $9.75 in the next year. This suggests a possible upside of 207.6% from the stock's current price. View analysts' price targets for Cumberland Pharmaceuticals. Who are some of Cumberland Pharmaceuticals' key competitors? Some companies that are related to Cumberland Pharmaceuticals include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Mylan (MYL), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors. What other stocks do shareholders of Cumberland Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cumberland Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), CymaBay Therapeutics (CBAY), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Xeris Pharmaceuticals (XERS), Akero Therapeutics (AKRO), Cerecor (CERC) and Evelo Biosciences (EVLO). Who are Cumberland Pharmaceuticals' key executives? Cumberland Pharmaceuticals' management team includes the following people: Mr. A. J. Kazimi, Founder, Chairman, Pres & CEO (Age 61)Mr. Michael P. Bonner, CFO and Sr. Director of Fin. & Accounting (Age 42)Mr. Leo B. Pavliv, Exec. VP of Operations & Chief Devel. Officer (Age 58)Mr. James Lowrance Herman, Sr. VP of National Accounts & Chief Compliance Officer (Age 64)Mr. Martin E. Cearnal, Exec. VP of Marketing & Sales, Chief Commercial Officer and Director (Age 74) What is Cumberland Pharmaceuticals' stock symbol? Cumberland Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPIX." Who are Cumberland Pharmaceuticals' major shareholders? Cumberland Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.09%). Company insiders that own Cumberland Pharmaceuticals stock include A J Kazimi, Caroline Young, Gordon R Bernard, Joey A Jacobs, Joseph C Galante and Kenneth Krogulski. View institutional ownership trends for Cumberland Pharmaceuticals. Which institutional investors are buying Cumberland Pharmaceuticals stock? CPIX stock was purchased by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Cumberland Pharmaceuticals stock in the last two years include A J Kazimi, Caroline Young, Joey A Jacobs, Joseph C Galante, and Kenneth Krogulski. View insider buying and selling activity for Cumberland Pharmaceuticals. How do I buy shares of Cumberland Pharmaceuticals? Shares of CPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cumberland Pharmaceuticals' stock price today? One share of CPIX stock can currently be purchased for approximately $3.17. How big of a company is Cumberland Pharmaceuticals? Cumberland Pharmaceuticals has a market capitalization of $47.99 million and generates $47.53 million in revenue each year. The specialty pharmaceutical company earns $-3,540,000.00 in net income (profit) each year or $0.23 on an earnings per share basis. Cumberland Pharmaceuticals employs 80 workers across the globe. What is Cumberland Pharmaceuticals' official website? The official website for Cumberland Pharmaceuticals is www.cumberlandpharma.com. How can I contact Cumberland Pharmaceuticals? Cumberland Pharmaceuticals' mailing address is 2525 WEST END AVENUE SUITE 950, NASHVILLE TN, 37203. The specialty pharmaceutical company can be reached via phone at 615-255-0068 or via email at [email protected] This page was last updated on 9/24/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
